WO1998017282A1 - Procedes d'utilisation d'un octosulfate de saccharose pour le traitement ou la prevention d'une infection a virus enveloppe - Google Patents
Procedes d'utilisation d'un octosulfate de saccharose pour le traitement ou la prevention d'une infection a virus enveloppe Download PDFInfo
- Publication number
- WO1998017282A1 WO1998017282A1 PCT/US1997/019181 US9719181W WO9817282A1 WO 1998017282 A1 WO1998017282 A1 WO 1998017282A1 US 9719181 W US9719181 W US 9719181W WO 9817282 A1 WO9817282 A1 WO 9817282A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- sucrose octasulfate
- pharmaceutically acceptable
- viral
- patient
- Prior art date
Links
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 title claims abstract description 112
- 238000000034 method Methods 0.000 title claims abstract description 66
- 230000009385 viral infection Effects 0.000 title claims abstract description 24
- 241000700605 Viruses Species 0.000 claims abstract description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 229960004291 sucralfate Drugs 0.000 claims abstract description 54
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims abstract description 52
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 208000036142 Viral infection Diseases 0.000 claims abstract description 18
- 230000003612 virological effect Effects 0.000 claims description 34
- -1 1592U88 Chemical compound 0.000 claims description 28
- 239000003443 antiviral agent Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 229960002555 zidovudine Drugs 0.000 claims description 17
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 17
- 239000003433 contraceptive agent Substances 0.000 claims description 16
- 230000029812 viral genome replication Effects 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 230000002254 contraceptive effect Effects 0.000 claims description 14
- 125000000129 anionic group Chemical group 0.000 claims description 13
- 230000003993 interaction Effects 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- 150000004676 glycans Chemical class 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 241000271566 Aves Species 0.000 claims description 8
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 241000251468 Actinopterygii Species 0.000 claims description 7
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 7
- 239000013060 biological fluid Substances 0.000 claims description 7
- 230000005540 biological transmission Effects 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 241000700586 Herpesviridae Species 0.000 claims description 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 6
- 241000712907 Retroviridae Species 0.000 claims description 6
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 6
- 230000000249 desinfective effect Effects 0.000 claims description 6
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 6
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims description 6
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 6
- 229960000523 zalcitabine Drugs 0.000 claims description 6
- 241000712464 Orthomyxoviridae Species 0.000 claims description 5
- 241000711504 Paramyxoviridae Species 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000710781 Flaviviridae Species 0.000 claims description 4
- 241000700739 Hepadnaviridae Species 0.000 claims description 4
- 241000711931 Rhabdoviridae Species 0.000 claims description 4
- 229960004150 aciclovir Drugs 0.000 claims description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 4
- 230000035606 childbirth Effects 0.000 claims description 4
- 229960004396 famciclovir Drugs 0.000 claims description 4
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229940087419 nonoxynol-9 Drugs 0.000 claims description 4
- 229920004918 nonoxynol-9 Polymers 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 4
- KCHIOGFOPPOUJC-UHFFFAOYSA-N (methylpyridazine piperidine ethyloxyphenyl)ethylacetate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCC1CCN(C=2N=NC(C)=CC=2)CC1 KCHIOGFOPPOUJC-UHFFFAOYSA-N 0.000 claims description 3
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 claims description 3
- QLOCVMVCRJOTTM-SDNRWEOFSA-N 1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CC)=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 QLOCVMVCRJOTTM-SDNRWEOFSA-N 0.000 claims description 3
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 claims description 3
- NMXDTPBZWZGMMO-UHFFFAOYSA-N 4-(2-methyl-5-propan-2-ylcyclohexyl)phenol Chemical compound C1C(C(C)C)CCC(C)C1C1=CC=C(O)C=C1 NMXDTPBZWZGMMO-UHFFFAOYSA-N 0.000 claims description 3
- GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 3
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 3
- 108010002069 Defensins Proteins 0.000 claims description 3
- 102000000541 Defensins Human genes 0.000 claims description 3
- 108010026389 Gramicidin Proteins 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 108060003100 Magainin Proteins 0.000 claims description 3
- 108010036176 Melitten Proteins 0.000 claims description 3
- 241000711386 Mumps virus Species 0.000 claims description 3
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 3
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 3
- GCQYYIHYQMVWLT-HQNLTJAPSA-N Sorivudine Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 GCQYYIHYQMVWLT-HQNLTJAPSA-N 0.000 claims description 3
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 3
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims description 3
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 3
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims description 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 3
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims description 3
- DIXRMZGIJNJUGL-UHFFFAOYSA-N arildone Chemical compound CCC(=O)C(C(=O)CC)CCCCCCOC1=CC=C(OC)C=C1Cl DIXRMZGIJNJUGL-UHFFFAOYSA-N 0.000 claims description 3
- 229950003470 arildone Drugs 0.000 claims description 3
- 229960002756 azacitidine Drugs 0.000 claims description 3
- 229960001169 brivudine Drugs 0.000 claims description 3
- 229960000724 cidofovir Drugs 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 claims description 3
- 229950003564 fiacitabine Drugs 0.000 claims description 3
- 229950008802 fialuridine Drugs 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 229960005102 foscarnet Drugs 0.000 claims description 3
- 229960002963 ganciclovir Drugs 0.000 claims description 3
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 3
- 229930000755 gossypol Natural products 0.000 claims description 3
- 229950005277 gossypol Drugs 0.000 claims description 3
- 229960004905 gramicidin Drugs 0.000 claims description 3
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 claims description 3
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 claims description 3
- 229960004716 idoxuridine Drugs 0.000 claims description 3
- 229960002751 imiquimod Drugs 0.000 claims description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001936 indinavir Drugs 0.000 claims description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 3
- 229960001627 lamivudine Drugs 0.000 claims description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 3
- 229950005339 lobucavir Drugs 0.000 claims description 3
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 claims description 3
- 229960001112 menfegol Drugs 0.000 claims description 3
- 229960000884 nelfinavir Drugs 0.000 claims description 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 3
- 229950008367 netivudine Drugs 0.000 claims description 3
- 229960000689 nevirapine Drugs 0.000 claims description 3
- 229940066429 octoxynol Drugs 0.000 claims description 3
- 229920002113 octoxynol Polymers 0.000 claims description 3
- 229960001179 penciclovir Drugs 0.000 claims description 3
- 229950011136 pirodavir Drugs 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 229960000329 ribavirin Drugs 0.000 claims description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 3
- 229960000311 ritonavir Drugs 0.000 claims description 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 3
- 229960001852 saquinavir Drugs 0.000 claims description 3
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical group C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 3
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 3
- 229950009279 sorivudine Drugs 0.000 claims description 3
- 229960001203 stavudine Drugs 0.000 claims description 3
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 3
- 229960003962 trifluridine Drugs 0.000 claims description 3
- 229940093257 valacyclovir Drugs 0.000 claims description 3
- 230000005570 vertical transmission Effects 0.000 claims description 3
- 229960003636 vidarabine Drugs 0.000 claims description 3
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- VFBJEDFCUUCMBQ-UHFFFAOYSA-O azanium;sodium;antimony(3+);oxygen(2-);tungsten Chemical compound [NH4+].[O-2].[Na+].[Sb+3].[W] VFBJEDFCUUCMBQ-UHFFFAOYSA-O 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 2
- 229960002656 didanosine Drugs 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 14
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 230000000699 topical effect Effects 0.000 abstract description 6
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 abstract description 5
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 36
- 230000000694 effects Effects 0.000 description 17
- 239000000499 gel Substances 0.000 description 14
- 239000002674 ointment Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000000840 anti-viral effect Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000014508 negative regulation of coagulation Effects 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 244000062730 Melissa officinalis Species 0.000 description 6
- 235000010654 Melissa officinalis Nutrition 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 239000000865 liniment Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000008297 liquid dosage form Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000008299 semisolid dosage form Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940124558 contraceptive agent Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 239000006194 liquid suspension Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000000606 toothpaste Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000792859 Enema Species 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- 241000712892 Arenaviridae Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 241000150452 Orthohantavirus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical group 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000713297 Influenza C virus Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000802 reproductive impairment Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000012873 virucide Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the use of sucrose octasulfate and pharmaceutically acceptable salts thereof, including sucralfate, the basic aluminum salt of sucrose octasulfate, to treat or prevent viral infections caused by enveloped viruses.
- Anionic, sulfated polysaccharides such as heparin, heparan sulfate, dermatan sulfate, pentosan sulfate and others have been shown to exhibit antiviral activity [M. Baba et al., Proc. Natl. Acad. Sci. USA. 85, pp. 6132-36 (1988)]. They have also been identified as in vitro inhibitors of enveloped viruses, including the HIV virus [M. Witvrouw et al., Antiviral Chem. Chemother., 5, pp. 345-59 (1994)], herpes simplex type 1 and type 2 viruses [Witvrouw et al., supra; B.
- anionic sulfated polysaccharides have been proposed as systemic antiviral agents with broad specificty against the enveloped viruses as a class.
- Anionic sulfated polysaccharides suffer from poor bioavailablilty following oral ingestion and demonstrate toxicity upon continuous intravenous infusion [Witvrouw et al., supra1. They also exhibit significant anticoagulant activity [R. Nagashima, J. Clin. Gastroenterol. , 3, pp. 103-10 (1981); F. A. Ofosue et al., Brit. J. He atol..
- heparin is a well-recognized and potent anticoagulant drug that is widely used clinically in the control of blood clotting. Increased bleeding in the course of antiviral therapy is an unacceptable side effect, given that enveloped viruses targeted by these agents are transmitted through contact with blood and other bodily fluids. Accordingly, these anionic sulfated polysaccharides have limited use as antiviral therapeutics or prophylactics. None have been approved for use as drugs, either in systemic or in topical form.
- the anticoagulant and antiviral activity observed for the anionic sulfated polysaccharides both appear to be critically dependent on the degree of polymerization of those molecules. Anticoagulant and antiviral activity decreases rapidly as the size of the polymer decreases.
- the anticoagulant activity of disaccharide fragments of heparin is no greater than negative controls [R. Nagashima, supra; R. J. Linhardt et al., J. Biol. Chem L.i./ 257, pp. 7310-13 (1982)]
- the antiviral activity of dextran sulfate is obliterated when that compound is digested down to disaccharide units [N. R. Hart an et al., AIDS Res. Hum. Retroviruses, 6, pp. 805-12 (1990)].
- sucrose octasulfate One particular anionic sulfated polysaccharide, sucrose octasulfate, and its well-known basic aluminum salt, sucralfate, have been used therpaeutically.
- United States Patent 3,432,489 describes these compounds.
- Sucralfate has been used for treating gastrointestinal ulcers or inflammed tissue.
- European patent application EP 0 640 346 refers to the use of sulphated mono- and di-saccharides to prevent inflammation. That application also refers to the use of sulphated saccharides to indirectly prevent viral infection by acting on the cell to be infected. Sucralfate, however has never been suggested to be able to kill virus directly.
- Sucralfate is an extremely safe drug, with a remarkably benign side-effects profile. Animal studies have shown that 1 gram/kg of body weight over 24 months is tolerated without toxicity. Sucralfate is one of a handful of drugs that has no known lethal dose.
- sucrose octasulfate and pharmaceutically acceptable salts thereof including the basic aluminum salt sucralfate
- sucrose octasulfate and pharmaceutically acceptable salts thereof including the basic aluminum salt sucralfate
- sucrose octasulfate and its salts can directly kill enveloped viruses by interacting with the positively charged coat of those viruses.
- sucrose octasulfate and sucralfate are devoid of anticoagulant activity [R. Nagashima, J. Clin. Gastroenterol, 3, pp. 117-27 (1981) ] .
- sucralfate ideal for use in preventing sexually transmitted enveloped viral diseases, such as herpes and HIV, even in a pregnant patient.
- sucrose octasulfate ideal for use in preventing sexually transmitted enveloped viral diseases, such as herpes and HIV, even in a pregnant patient.
- the present invention provides methods for treating or preventing enveloped viral infection in a patient using sucrose octasulfate or a pharmaceutically acceptable salt thereof. The methods may also be used to prevent transmission of enveloped virus during casual contact (including touching and kissing), sexual contact or during childbirth.
- the invention also provides methods for using sucrose octasulfate or its salts to disinfect various devices that come into contact with bodily fluids, such as contraceptive devices (condoms, sponges, diaphragms) , surgical gloves, surgical tools, napkins and tissues.
- contraceptive devices condoms, sponges, diaphragms
- surgical gloves surgical tools, napkins and tissues.
- the invention also provides methods for disinfecting liquid preparations, such as blood, plasma, sperm and ova, as well as laboratory and clinical samples, with sucrose octasulfate and its salts.
- the invention further provides methods of preventing transmission of enveloped viral infection in veterinary settings and in the production of animals for food.
- the invention also provides pharmaceutical combinations comprising sucrose octasulfate or a pharmaceutically acceptable salt thereof, together with an antiviral agent or a contraceptive agent.
- the present invention capitalizes on the favorable properties of sucrose octasulfate, including its ability to be administered in high doses without toxicity or side effects; its affinity for damaged epithelium which is known to be a preferred site for viral entry; and its ability to form non-covalent gels or remain in a liquid state depending upon the particular salt used.
- This latter property allows a choice between a long-acting, slow release dosage form of the sucrose octasulfate (gel) , and a rapidly cleared, high activity dosage form (liquid) , depending upon the particular anti-viral use desired.
- Other formulation options are described below.
- the present invention provides methods utilizing sucrose octasulfate or pharmaceutical salts thereof for the prevention or treatment of an enveloped virus infection through the direct interaction of those compounds with the virus.
- the sucrose octasulfate salts used in the methods of this invention are characterized by several advantages. They do not disrupt the integrity of the target epithelial surface. Accordingly, they do not increase the risk of viral infection. In addition, they have no known toxic or tumorigenic effects. In addition, they have no anticoagulant activities, contraceptive effects, or other reproductive impairments.
- sucrose octasulfate or its pharmaceutically acceptable salts exert their therapeutic and prophylactic effects by interacting with the positively-charged regions of viral envelope proteins, such as the V3 region of gpl20 on HIV.
- sucrose octasulfate or a pharmaceutically acceptable salt thereof will inhibit the ability of such virus to enter an uninfected cell.
- the invention provides a pharmaceutical combination for the prophylaxis or treatment of an enveloped viral infection in a patient comprising: an amount of a sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce or prevent viral replication in said patient via direct interaction with said virus; an antiviral agent selected from a reverse transcription inhibitor, a viral protease inhibitor, a viral polymerase inhibitor and an anionic sulfated polysaccharide polymer comprising at least three repeating units; and a pharmaceutically acceptable carrier.
- sucrose octasulfate or pharmaceutically acceptable salt thereof useful in these combinations may be obtained commercially or may be synthesized by conventional techniques (see United States patent 3,432,489, the disclosure of which is incorporated herein by reference) .
- these compounds may be conveniently synthesized from commercially available starting materials.
- compositions of sucrose octasulfate useful in the combinations of this invention may include organic or inorganic, acid or base salts.
- the combinations comprise a base salt of sucrose octasulfate derived from alkaline or alkali earth metal.
- a base salt of sucrose octasulfate derived from alkaline or alkali earth metal.
- an aluminum or potassium salt of sucrose octasulfate is employed.
- the aluminum salt better known as sucralfate, forms a gel.
- the potassium salt is completely soluble.
- sucrose octasulfate or a pharmaceutically acceptable salt thereof as used in the combinations of this invention may be chemically modified by appending appropriate functionalities to enhance selective biological properties.
- modifications are well recognized in the art and include those which increase topical delivery or binding affinity to epithelial surfaces, or those which are compatible with the chemistry of the target surface.
- the antiviral agent present in the combination of this invention may be selected from a wide range of known reverse transcription inhibitors, viral protease inhibitors, viral polymerase inhibitors or anionic sulfated polysaccharide polymers comprising at least three repeating units.
- a viral polymerase inhibitors is employed, it is preferably selected from zidovudine ("AZT") , dianosine, zalcitabine, lamivudine, stavudine, nevirapine, 1592U88, or PMEA.
- a viral protease inhibitor is employed in the combinations of this invention, it is preferably selected from saquinavir, ritonavir, indinavir, nelfinavir or VX-478.
- a viral polymerase inhibitor is used, it is preferably selected from acyclovir, brivudin, cidofovir, famciclovir, fiacitabine, fialuridine, foscarnet, FTC, ganciclovir, GG- 167, idoxuridine, imiquimod, lobucavir, n-docosanol, netivudine, penciclovir, pirodavir, ribavirin, sorivudine, trifluridine, valaciclovir, dideoxycytidine, 5-azacytidine, or vidarabine.
- the additional second antiviral agent is AZT, VX-478, acyclovir or famciclovir.
- any conventional pharmaceutically acceptable carrier or adjuvant may be utilized in the combinations of this invention.
- These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium, trisilicate, polyvinyl pyrrolidone, cellulose-based substances and polyethylene glycol.
- Adjuvants for topical or gel base forms may be selected from the group consisting of sodium carboxymethylcellulose, polyacrylates, polyoxyethylene-polyoxpropylene-block polymers, polyethylene glycol, natural and synthetic gum bases, and wood wax alcohols.
- Formulations may include any excipient or carrier which may be added to sucrose octasulfate or pharmaceutical salts thereof, without affecting its biological effect.
- Pharmaceutical combinations of the present invention may be administered to epithelial surfaces or the body, or may be adminstered by parenteral techniques or by an implanted resevoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the combinations of the present invention may be topically administered to any epithelial surface.
- An "epithelial surface” is defined as an area of tissue that covers external surfaces of a body, or which and lines hollow structures including, but not limited to, cutaneous and mucosal surfaces.
- Such epithelial surfaces include oral, pharyngeal, esophogeal, pulmonary, ocular, aural, nasal, buccal, lingual, vaginal, cervical, genitourinary, alimentary, and anorectal surfaces.
- compositions of the present invention may be formulated in a variety of conventional forms employed for topical administration. These include, for example, semi-solid and liquid dosage forms, such as liquid solutions or suspensions, suppositories, douches, enemas, gels, creams, emulsions, lotions, slurries, powders, sprays, lipsticks, foams, pastes, toothpastes, ointments, salves, balms, douches, drops, troches, chewing gums, lozenges, mouthwashes, rinses. Standard and well-understood formulation strategies for topical agents can be applied to sucrose octasulfate or a pharmaceutically acceptable salt thereof in order to enhance the persistence and residence time of the drug, and to improve the prophylactic efficacy achieved.
- semi-solid and liquid dosage forms such as liquid solutions or suspensions, suppositories, douches, enemas, gels, creams, emulsions, lotions, slurries
- the sucrose octasulfate combination is formulated into a topical cream or gel.
- Such formulations are particularly useful, for example, for treatment or prevention of vaginal enveloped viral infections and treatment of viral infections of the oral cavity, including cold sores caused by herpes labialis .
- topical formulations may be used to treat or prevent enveloped viral infections of eye, the skin, or the lower intestinal tract. Suitable topical formulations are may be readily prepared for each of these areas or organs. Topical application for the lower intestinal tract can be effected in a rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches may also be used.
- the pharmaceutical combinations of this invention may also be administered by nasal aerosol or inhalation.
- Such combinations are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- the pharmaceutical combinations may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
- the pharmaceutical combinations may be formulated in an ointment such as petrolatum.
- the pharmaceutical combinations of this invention may be administered in the form of suppositories for rectal administration.
- suppositories for rectal administration.
- suppositories can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
- Sucrose octasulfate is a particularly preferred pharmaceutical salt of sucrose octasulfate in the combinations of this invention due to its formation of an anionic gel in dilute acid and its ability to bind to and protect ulcerated areas of the gastrointestinal tract.
- the pharmaceutical combinations of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, gums, aqueous suspensions or solutions.
- carriers which are commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried corn starch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- Sterile injectable forms of the combinations of this invention may be aqueous or oleaginous suspension.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
- a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1, 3-butanediol .
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di- glycerides.
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- oils such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
- the antiviral agent is present in amounts ranging from 50% to 100% of the amounts normally administered for that agent when it is used in a monotherapy.
- the remaining part of the combination will be made up of carrier and, if appropriate, water.
- Sucrose octasulfate or a pharmaceutically acceptable salt thereof will represent some percentage of the total dose in other dosage forms, including liquid solutions or suspensions, suppositories, douches, enemas, gels, creams, emulsions, lotions, slurries, powders, sprays, lipsticks, foams, pastes, toothpastes, ointments, salves, balms, douches, drops, troches, lozenges, mouthwashes, rinses and others.
- Creams and gels are typically limited by the physical chemical properties of the delivery medium to concentrations less than 20% (e.g., 200mg/gm) . For special uses, far less concentrated preparations can be prepared, (e.g., lower percent formulations for pediatric applications) .
- sucrose octasulfate or a pharmaceutically acceptable salt thereof over many decades of clinical use as an anti-ulcerant [W. R. Garnett, Clin. Pharm. , 1, pp. 307-14
- sucrose octasulfate the minimum amount present in the combinations of this invention that is effective in treating or preventing viral disease due to direct interaction with the virus should produce be 1 x 10 mg/ml. If sucralfate is employed the minimum effective concentration should be 1 x 10 mg/ml.
- the invention provides a pharmaceutical combination for preventing conception and for the prophylaxis or treatment of an enveloped viral infection in a patient comprising: an amount of a sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce or prevent viral replication in said patient via direct interaction with said virus; an amount of a contraceptive effective to prevent conception; a pharmaceutically acceptable carrier.
- the sucrose octasulfate component can be in any salt form mentioned above.
- it is the aluminum salt sucralfate.
- the contraceptive agent is selected from nonoxynol-9, nonoxynol-11, octoxynol, sodium docusate, HPA-23, gossypol, menfegol, arildone, gramicidin, magainins, defensins, melittin, or amphotercin B.
- the contraceptive agent is nonoxynol-9.
- the carrier employed in the sucrose octasulfate/contraceptice agent combinations of this invention should be compatible with vaginal administration and/or coating of contraceptive devices.
- the choice of particular carrier for these uses is well known in the art.
- These combinations may be utilized in solid, semi-solid and liquid dosage forms, such as diaphragm jelly, douches, foams, ointments, creams, balms, gels, salves, pastes, slurries, vaginal suppositories, sexual lubricants, and coatings for devices such as condoms, contraceptive sponges, cervical caps and diaphragms.
- the invention provides a method for treating or preventing an enveloped virus infection in a patient comprising the step of administering to said patient a composition comprising: an amount of a sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce or prevent viral replication in said patient via direct interaction with said virus; and a pharmaceutically acceptable carrier.
- a composition comprising: an amount of a sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce or prevent viral replication in said patient via direct interaction with said virus; and a pharmaceutically acceptable carrier.
- sucrose octasulfate form and of carrier are the same as described above for sucrose octasulfate/antiviral agent combinations.
- this method comprises the additional step of administering to said patient, either as part of the same dosage form or as a separate dosage form, an antiviral agent selected from a reverse transcription inhibitor, a viral protease inhibitor, a viral polymerase inhibitor and an anionic sulfated polysaccharide polymer comprising at least three repeating units.
- an antiviral agent selected from a reverse transcription inhibitor, a viral protease inhibitor, a viral polymerase inhibitor and an anionic sulfated polysaccharide polymer comprising at least three repeating units.
- the methods comprises the additional step of administering to said patient, either as part of the same dosage form or as a separate dosage form, an amount of a contraceptive effective to prevent conception.
- sucrose octasulfate and for the contaceptive agent are the same as those described above for the sucrose octasulfate/ contraceptive agent pharmaceutical combinations.
- Combinational therapies utilized in the methods of this invention may also exert an additive or synergistic effect, particularly when the viricidal activity of each component operates via a different mechanism.
- the reduction in effective therapeutic dose achieved with such combinations may be additive or synergistic.
- dramatically lower doses of both the conventional antiviral agent and of sucrose octasulfate or a pharmaceutically acceptable salt thereof will lead to effective therapy nonetheless.
- the occurrence of any side effects associated with the added conventional antiviral agent may be reduced or avoided — where, as stated above, the toxicity of sucrose octasulfate or its basic aluminum salt, sucralfate is known to be minimal from prior clinical experience.
- Another advantage of such combination therpy regimens is that they may delay the emergence of viral resistance.
- a patient according to this invention is an animal, including a human.
- Animal patients include, but are not limited to, other mammals, birds, and fish.
- the patient is a human.
- the methods of this invention are carried out for a period of time sufficient to prevent viral replication in a patient or to prevent transmission of enveloped virus from an infected patient to another patient through the direct interaction of sucrose octasulfate or its salts with the virus.
- Such enveloped viruses include, for example, virus from the genera Retroviridae , Herpesviridae, Orthomyxoviridae, Paramyxoviridae, Hepadnaviridae , Flaviviridae , Togaviridae, Rhabdoviridae, Poxviridae, Arenaviridae, Coronoviridae, Bunyaviridae and Filoviridae.
- Retroviridae that may be treated or prevented using the methods of this invention include, for example, human immunodeficiency virus type 1 and the human immunodeficiency virus type 2 lentiviruses, foamy viruses and human T-cell leukemia viruses.
- Herpesviridae that may be treated or prevented using the methods of this invention include, for example, herpes simplex type 1 and herpes simplex type 2 viruses, varicella-zoster viruses, cytomegaloviruses, lymphoproliferative herpesviruses and Epstein-Barr virus.
- Orthomyxoviridae that may be treated or prevented using the methods of this invention include, for example, influenza A, influenza B and influenza C viruses.
- Paramyxoviridae that may be treated or prevented using the methods of this invention include, for example, respiratory syncytial virus, mumps virus, parainfluenza viruses and measles-like viruses.
- Hepadnaviridae that may be treated or prevented using the methods of this invention include, for example, hepatitis B virus.
- Flaviviridae that may be treated or prevented using the methods of this invention include, for example, hepatitis C virus, yellow fever virus, dengue virus and tick-borne encephalitis viruses.
- Togaviridae that may be treated or prevented using the methods of this invention include, for example, rubella virus .
- Rhabdoviridae that may be treated or prevented using the methods of this invention include, for example, rabies virus and vesicular stomatitis virus.
- Poxviridae that may be treated or prevented using the methods of this invention include, for example, vertebrate and avian poxviruses and vaccinia viruses.
- Arenaviridae that may be treated or prevented using the methods of this invention include, for example, the arenaviruses.
- Coronaviridae that may be treated or prevented using the methods of this invention include, for example, the coronaviruses.
- Bunyaviridae that may be treated or prevented using the methods of this invention include, for example, the hantaviruses.
- Filoviridae that may be treated or prevented using the methods of this invention include, for example, Marburg, Reston and Ebola viruses.
- the enveloped viral infection to be treated is one wherein the virus if from the genera Retroviridae, Herpesviridae, Orthomyxoviridae, Paramyxoviridae, Hepadnaviridae, Flaviviridae, or Rhabdoviridae. More preferably, the virus is type 1 or type 2 human immunodeficiency virus, type 1 or type 2 herpes simplex virus, varicella zoster virus,
- Epstein-Barr virus Epstein-Barr virus, cytomegalovirus, influenza type A, B, or C virus, respiratory scincytial virus, mumps virus, hepatitis B virus, hepatitis C virus, encephalitis virus, rabies virus, or dengue fever-inducing virus.
- the virus is type 1 or type 2 human immunodeficiency virus or type 1 or type 2 herpes simplex virus.
- compositions of this invention are also useful in the treatment or prevention of respiratory complications in neonates resulting from paramyxovirus infection, measles, German measles, conjunctivitis, other non-sexually transmitted enveloped virus-induced diseases, herpes-associated Karposi's sarcoma, other viral-assocated cancers, encephalitis and yellow fever.
- the methods of this invention are used to treat an epithelial surface of a patient.
- the epithelial surface is selected from oral, pharyngeal, esophogeal, pulmonary, ocular, aural, nasal, buccal, lingual, vaginal, cervical, genitourinary, alimentary, or anorectal surfaces.
- the methods of this invention are useful to prevent and treat infections that cause oral and esophageal sores.
- Oral sores may arise by infection from a number of enveloped viruses including
- Herpesviridae including herpes simplex type I and type II viruses, and Retroviridae such as the human immunodeficiency viruses.
- Sucrose octasulfate or a pharmaceutically acceptable form thereof, used in this embodiment may be in several forms including solid, semi-solid and liquid dosage forms, including liquid solutions or suspensions, troches, lozenges, mouthwashes, rinses, pastes toothpastes, ointments, salves, balms, lipsticks, gels, creams, emulsions, lotions, slurries, powders, sprays, foams, and drops .
- the methods of this invention are useful for treating and preventing infections that cause genital sores.
- Genital sores may arise from infection by a number of enveloped viruses including Herpesviridae such as the herpes simplex type I and type II viruses, retroviridae such as the human immunodeficiency viruses.
- Sucrose octasulfate or a pharmaceutically acceptable salt thereof, used in this embodiment may be incorporated into several forms including solid, semi-solid and liquid dosage forms, diaphragm jelly, douches, sprays, foams, lotions, ointments, creams, balms, powders, gels, salves, pastes, slurries, suppositories, sexual lubricants, and including coatings or for devices such as condoms, diaphragms, feminine napkins, and tampons.
- the methods of this invention are useful for treating and preventing respiratory infections.
- Respiratory infections be caused by a number of enveloped viruses including Orthomyxoviridae such as the influenza virus, Paramyxoviridae such as the respiratory syncytial virus, parainfluenza virus, hantavirus, and cytomegalovirus.
- Sucrose octasulfate or pharmaceutically acceptable salt thereof, used in this embodiment may be in several forms including solid, semi- solid and liquid dosage forms, including liquid solutions or suspensions, troches, lozenges, mouthwashes, rinses, pastes toothpastes, ointments, salves, balms, lipsticks, gels, creams, emulsions, lotions, slurries, powders, sprays, foams, and drops.
- the invention provides a method for preventing vertical transmission of an enveloped virus from a mother to a child during childbirth, which comprises the step of treating said mother prior to or during labor with a composition comprising: an amount of a sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce or prevent viral replication in said child via direct interaction with said virus; and a pharmaceutically acceptable carrier.
- This method is carried out by topically administering to the mother's birth canal during or prior to labor a therapeutically effective concentration of sucrose octasulfate or a pharmaceutically acceptable salt thereof.
- Recent data suggests a correlation between maternal viral load and extended contact with vaginal and cervical secretions by the neonate, with the incidence of vertical transmission of HIV to newborns [T.
- sucrose octasulfate composition or combination utilized should be compatible with the treatment of neonates.
- carrier and antiviral agent if utilized for use in childbirth is well known in the art.
- the invention provides a method for disinfecting a health care device which is designed to come into contact with a patient, said method comprising the step of contacting the health care device with a composition comprising an amount of a sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce the viral titer on said health care device prior to said device coming into contact with said patient.
- the device is selected from a contraceptive device, a plastering material, a bandage, a sponge, a napkin, a strip, a tissue, a protective external covering used in medicine, a surgical device, a dental device, a laboratory device, surgical gloves, a surgical gown, and a surgical mask.
- sucrose octasulfate or a pharmaceutically acceptable salt thereof may be mixed with a talcum lubricant powder used to line surgical gloves.
- the amounts of sucrose octasulfate salts, as well as the antiviral agent (if present), carriers and adjuvants that are necessary for the coating or treatment of said devices that are necessary to treat the aforementioned devices and biological materials for the purpose of disinfecting said devices prior to coming into contact with animals will be dependent on the type, size, surface area, consistency, intended use of this device.
- the devices will be prepared in such a way as to be treated with a therapeutically or prophylactically effective amount and for a period of time sufficient to prevent the transmission of an enveloped virus from said device.
- One skilled in the art will be able to determine the most appropriate formulations for treatment of said devices.
- the invention provides a method for disinfecting a biological fluid comprising the step of contacting said fluid with an amount of sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce the viral titer in said biological fluid.
- the biological fluid is selected from blood, plasma, ova, or semen.
- the sucrose octasulfate or salt thereof may be added directly to the biological fluid.
- it may be coupled to a solid support comprising, for example, plastic or glass beads, or a filter, which is placed in contact with those samples.
- Sucrose octasulfate and its salts are particularly advantageous for purifying blood because of its lack of anticoagulant activity.
- the invention provides a method for preventing the transmission of an enveloped viral infection between animals, birds or fish, comprising the step of contacting a food, water, or living environment of said animals, birds or fish with an amount of a sucrose octasulfate or a pharmaceutically acceptable salt thereof, sufficient to reduce or prevent viral replication in said animals, birds or fish via direct interaction with said virus.
- sucrose octasulfate or pharmaceutically acceptable salts thereof for living things depends upon the target virus, previous therapy, the extent of desired treatment, the target area of treatment, the body weight of patient, drug combinations, severity of the disease, the patient's health status and response to the sucrose octasulfate and the judgment of the treating physician.
- the sucrose octasulfate may be administered to the patient in any pharmaceutically acceptable topical dosage form, at one time or over a series of treatments.
- a maintenance dose of the sucrose octasulfate or a pharmaceutically acceptable salt thereof alone or in combination with a second antiviral agent may be administered, if necessary. Subsequently, the dosage or the frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- Example l cell lines and Materials Sucralfate was purchased as a powder from Spectrum Chemical Manufacturing. Corp. (Gardena, CA) or as a tablet from Marion Merril Dow (Kansas City, Mo) . Sucrose octasulfate powder was purchased from U.S. Pharmacopeial Convention, Inc., Rockville, MD.
- Sucralfate stock suspensions were prepared by dissolving lg of sucralfate powder in 4mL of RPMI-1640 medium with 0.01 N HC1 added. The sucralfate stock suspension (at 250 mg/ml) was stored at 4°C prior to use. Sucrose octasulfate solutions were prepared by dissolving 100 mg sucrose octasulfate in 4mL of RPMI-1640 medium; the 25 mg/mL sucrose octasulfate solutions were also stored as above . Human monocytes and cell lines (C8166, H9, U-937) were prepared in RPMI-1640 media, supplemented with 20% fetal calf serum. Peripheral blood mononuclear cells (PBMCs) were grown in the same medium to which IL-2 (5%, Cellular Products) and phytohemagglutinin (5 ⁇ g/mL) had been added.
- PBMCs Peripheral blood mononuclear cells
- HTLV-IIIB was provided by R.C. Gallo, NCI, Bethesda, MD. HIV-1 18a and 18c was provided by Dr. V.A. Johnson, University of Alabama, Birmingham, AL. HIV-1-9400232 (HIV-194) , is a low passage clinical isolate obtained from a participant in an AIDS clinical trial.
- Example 2 Cvtotoxicity Assays Given that sucralfate suspensions interfere visually with the determination of cell viability by trypan blue staining, cytotoxic effects of the drug were determined by monitoring cellular proliferation, as assayed by 3H- thymidine incorporation.
- One ⁇ Ci thymidine DuPont-NEN, Boston, MA
- 3 H- thymidine cultures were incubated for 4-6 hours at 37°C and 3 H-TdR incorporation was determined.
- TCID 50 is defined as the viral titer that will infect 50% of the cells in a tissue culture experiment.
- 100 ⁇ L aliquots of the sucralfate or sucrose octasulfate dilutions were added to each well.
- supernatants from the test cultures were assayed for viral replication as described below. HIV virus replication assays were performed essentially as according to D.D.
- a sample containing unlabelled p24 antigen was mixed with a fixed amount of 125 ⁇ labelled p24 and a fixed limiting amount of rabbit anti-p24 antibody.
- the samples were incubated overnight at room temperature.
- a goat anti-rabbit immunoglobulin preparation was then added to the test mixture, to precipitate the anti-p24 antibody.
- the samples were centrifuged and the supernatant was aspirated. Pelletted 125 I labelled p24 was quantitated for each sample by gamma counting and comparison to a standard curve .
- sucralfate and sucrose octasulfate were determined.
- IC50 values concentration of sucralfate and sucrose octasulfate required to inhibit 50% of viral replication.
- TC50 values indicate the concentration of sucralfate or sucrose octasulfate that inhibited 50% of cellular proliferation as measured by tritiated thymidine incorporation (see protocol Example 2, results Table 1) .
- the inhibitory activity of sucralfate tablet and sucralfate powder can be compared within cell lines on Table 1.
- sucralfate tablet is approximately 4.5 fold more effective against an acutely infected H9 cell line than a chronically infected cell line.
- Sucralfate powder and sucrose octasulfate both were more effective against acutely infected H9 cells than chronically infected H9 cells .
- sucralfate tablet suspension inhibited HIV replication more effectively in HIV 18C and HIV 194 isolates than in HIV 18a isolate.
- sucralfate tablet suspensions did not have different effects on the level of HIV infection in monocytes challenged with HIV 18a or HIV 18c (see IC50 values, Table 1) . Therefore, the treatment or prophylaxis of HIV infection using sucralfate and sucrose octasulfate will need to be adjusted depending on the targeted cell and viral strain.
- Example 4 Svner ⁇ istic Effect of AZT and Sucrose Octasulfate A ⁇ ainst HTV 2 x 10 5 PBMCs in 100 ⁇ L were exposed to 100 TCID 50 of HIV-1 inoculum (isolates 18c and 18c) in 50 ⁇ L without subsequent washing of cells.
- sucrose octasulfate or AZT suspensions were added to each well for a final concentration of 4 nM, InM, 0.25nM, 0.064nM, or 0.016nM of AZT or a final concentration 4 mg/ml, 1 mg/ml, 0.25 mg/ml, 0.064 mg/ml, or 0.016 mg/ml of sucrose octasulfate.
- AZT was tested in combination with sucrose octasulfate such that 4 nM AZT was tested with 4 mg/ml sucrose octasulfate, 1 nM AZT was tested with 1 mg/ml of sucrose octasulfate, and so on. Viral replication was assayed by quantitating HIV p24 antigen production four days after infection (see Example 3) .
- sucrose octasulfate alone inhibited the infection of 50% of the cells (IC50) at 0.99 mg/ml.
- AZT inhibited the infection of 50% of the cells (IC50) at 3.35 nM.
- Sucrose octasulfate and AZT combined was able to inhibit 50% of the tested cells at a concentration of 0.65 nM AZT and 0.35-0.45 mg/ml sucrose octasulfate. Therefore, the results indicate that five fold less AZT and approximately 2.5 fold less sucrose octasulfate are required to achieve 50% viral inhibition than by either AZT or sucrose octasulfate alone. In a similar study using HIV isolate 18c, ten fold less AZT and five fold less sucrose octasulfate was needed to achieve 50% viral inhibition than when either one was used alone.
- Sucralfate was dissolved in solutions with varying pH prior to addition to cells. Inhibition of viral replication was measured four days after infection by p24 antigen production (see Example 3) . Sucralfate dissolved in a solution of pH 6.0 was more inhibitory than sucralfate dissolved in pH 3.0 (compare IC50 values, Table 2). Sucralfate was also found to be more soluble at pH 5.61-6.40 than pH 3.0. Therefore, the activity of sucralfate appears related to its solubility. TABLE 2 p24 Antigen ng/mL (Day 4 after infection)
- HSV-1 (strain HSV-690) and HSV-2 (strain SKB-1) and the AS49/20S cell line were obtained from Dr. Adriana Weinberg, University of Colorado Health Sciences.
- Trisodium phosphonoformate (PFA) a viral polymerase inhibitor, was used as a positive control.
- HSV-1 or HSV- 2 (MOI 0.005 pfu/cell) and sucralfate or sucrose octasulfate was added to AS49/20S cells, incubated at 37°C in 5% C0 2 , and observed for evidence of cytopathic effect (CPE) over a period of 0 to 48 hours after viral innoculation.
- CPE cytopathic effect
- sucralfate and sucrose octasulfate inhibited 50% of CPE in HSV-1 infected cells at approximately 0.125 to 2 mg/ml. Severity of CPE depended upon the point of addition of drug or viral challenge of HSV-1. For example, in Tables 3a-c, sucralfate and sucrose octasulfate were more effective against HSV-1 when added simultaneously with virus than when added after the virus was allowed to contact the cell (compare IC50 values of preinfected cells and cells not preinfected) .
- sucrose octasulfate over a final concentration range of 0 to 8 mg/ml was tested essentially as described above. However, viral activity was quantitated by counting the number of plaques formed for each infection (see results in Table 4, below) .
- HSV-2 like HSV-1, was more effectively inhibited by sucrose ocatasulfate or sucralfate when the cells were not pre-treated with virus (See Table 4, compare IC50 values of preinfected cells and cells not preinfected) .
- sucrose octasulfate inhibited 50% of plaque formation by HSV-2 when no drug was added. No significant toxicity was observed at the concentrations and formulations of sucralfate or sucrose octasulfate as recited in Table 3 or Table 4.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU49955/97A AU4995597A (en) | 1996-10-23 | 1997-10-23 | Methods of using sucrose octasulfate to treat or prevent enveloped virus infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73546096A | 1996-10-23 | 1996-10-23 | |
US08/735,460 | 1996-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998017282A1 true WO1998017282A1 (fr) | 1998-04-30 |
Family
ID=24955900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/019181 WO1998017282A1 (fr) | 1996-10-23 | 1997-10-23 | Procedes d'utilisation d'un octosulfate de saccharose pour le traitement ou la prevention d'une infection a virus enveloppe |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4995597A (fr) |
WO (1) | WO1998017282A1 (fr) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015566A1 (fr) * | 1997-09-23 | 1999-04-01 | Dalhousie University | Composition et preparation pharmaceutique la contenant pour le traitement de l'herpes et autres maladies virales apparentees |
DE19841794A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden |
DE19841795A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Sterole und Sterolderivate) und Mikrobiziden |
DE19841796A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden |
EP1239923A2 (fr) * | 1999-12-20 | 2002-09-18 | New Pharma Research Sweden AB | Compositions veterinaires stabilisees, contenant plusieurs agents antiviraux |
JP2008239541A (ja) * | 2007-03-27 | 2008-10-09 | Kanmonkai:Kk | 魚介類の感染予防剤 |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01149730A (ja) * | 1987-12-07 | 1989-06-12 | Osaka Prefecture | レトロウイルス増殖抑制剤 |
WO1989007932A1 (fr) * | 1988-02-26 | 1989-09-08 | Niels Bukh A/S | Procede servant a traiter des etats pathologiques des dents ou de leurs tissus de support |
EP0640346A1 (fr) * | 1987-12-21 | 1995-03-01 | BM Research A/S | Utilisations de sucres sulfates contre inflammation |
WO1995035103A1 (fr) * | 1994-06-20 | 1995-12-28 | Kurt Berg | Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition |
-
1997
- 1997-10-23 WO PCT/US1997/019181 patent/WO1998017282A1/fr active Application Filing
- 1997-10-23 AU AU49955/97A patent/AU4995597A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01149730A (ja) * | 1987-12-07 | 1989-06-12 | Osaka Prefecture | レトロウイルス増殖抑制剤 |
EP0640346A1 (fr) * | 1987-12-21 | 1995-03-01 | BM Research A/S | Utilisations de sucres sulfates contre inflammation |
WO1989007932A1 (fr) * | 1988-02-26 | 1989-09-08 | Niels Bukh A/S | Procede servant a traiter des etats pathologiques des dents ou de leurs tissus de support |
WO1995035103A1 (fr) * | 1994-06-20 | 1995-12-28 | Kurt Berg | Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 8929, Derwent World Patents Index; Class B03, AN 89-211474, XP002055990 * |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015566A1 (fr) * | 1997-09-23 | 1999-04-01 | Dalhousie University | Composition et preparation pharmaceutique la contenant pour le traitement de l'herpes et autres maladies virales apparentees |
DE19841794A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden |
DE19841795A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Sterole und Sterolderivate) und Mikrobiziden |
DE19841796A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden |
EP1239923A2 (fr) * | 1999-12-20 | 2002-09-18 | New Pharma Research Sweden AB | Compositions veterinaires stabilisees, contenant plusieurs agents antiviraux |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
JP2008239541A (ja) * | 2007-03-27 | 2008-10-09 | Kanmonkai:Kk | 魚介類の感染予防剤 |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US12138311B2 (en) | 2009-10-02 | 2024-11-12 | Journey Medical Corporation | Topical tetracycline compositions |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10946101B2 (en) | 2009-10-02 | 2021-03-16 | Vyne Therapeutics Inc. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Also Published As
Publication number | Publication date |
---|---|
AU4995597A (en) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998017282A1 (fr) | Procedes d'utilisation d'un octosulfate de saccharose pour le traitement ou la prevention d'une infection a virus enveloppe | |
AP1163A (en) | Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases. | |
EP1030547B1 (fr) | Procedes pour prevenir et traiter les infections bacteriennes au moyen d'excipients a base d'acetophtalate de cellulose ou de phtalate d'hydroxypropylmethylcellulose | |
US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
EA011298B1 (ru) | Применение бактерицидных пиримидинов для профилактики передачи вич половым путём и фармацевтические композиции на их основе | |
SA96160590B1 (ar) | تركيبة صيدلانية | |
PL188470B1 (pl) | Kompozycja stosowana przeciw mikroorganizmom w zakażeniach wirusem opryszczki i innych chorobach infekcyjnych | |
US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
US4462986A (en) | Synergistic anti-herpes compositions | |
JP2008543885A (ja) | 皮膚病変治療用組成物 | |
US5491135A (en) | Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals | |
CA2109435C (fr) | Compositions d'acide n-(phosphonoacetyl)-l-aspartique et methodes pour leur utilisation comme agents antiviraux a large spectre | |
Nadelman et al. | Herpes simplex virus infections: new treatment approaches make early diagnosis even more important | |
JP2006515361A (ja) | ヘルペスウイルス感染の症候を治療又は予防する方法 | |
WO2015167368A1 (fr) | Hexahydrate de dichlorhydrate de tétrachlorure de 4,6-di(3,12-diaza-6,9-diazoniadispiro[5.2.5.2]hexadécan-1-yl)-2-méthyl-5-nitropyrimidine utilisé pour pour le traitement de l'infection herpétique et composition pharmaceutique topique | |
EP2849735A1 (fr) | Crème vaginale pour le traitement d'une infection au papillome comprenant du docosanol, du curcuma, de l'amla et de l'aloe | |
JPH0138770B2 (fr) | ||
RU2204385C2 (ru) | 2,4-дихлорбензиловый спирт и амилметакрезол против вич-инфекции | |
WO1999043333A1 (fr) | Utilisations therapeutiques et prophylactiques de disaccharides substitues de charge negative | |
US5900411A (en) | Method of treatment of Kaposi's sarcoma | |
JPH08208502A (ja) | 抗エイズウイルス剤の効果増強剤 | |
US20050241645A1 (en) | Composition for preventing the transmission of human immunodeficiency syndrome virus | |
MXPA99008750A (es) | Prevencion y tratamiento antimicrobianos de virus de inmunodeficiencia humana y otras enfermedades infecciosas | |
GB2224649A (en) | Fusidic acid anti-viral compositions | |
WO2019165312A1 (fr) | Composition pharmaceutique pour infections virales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998519633 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |